X4 Pharmaceuticals

Company snapshot

We are a fully integrated, commercial-stage biopharmaceutical company driving progress for people living with rare immune disorders. We listen to people whose challenges have been long overlooked, understand their needs, and develop solutions to their most urgent and critical health concerns. Our FDA-approved medication XOLREMDI® (mavorixafor) is commercially available in the U.S. in its first ind

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 16 US patent(s) indexed to this assignee profile.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for X4 Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Peking University Biologics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for X4 Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   Mavorixafor, Mavorixafor Placebo Capsules — Phase 3

2. Jun 8, 2026 Clinical update

   Mavorixafor, Placebo to Test IMP — Phase 3

3. Jun 8, 2026 Clinical update

   Mavorixafor — Phase 1

4. Jun 8, 2026 Clinical update

   X4P-001 — Phase 1

5. May 23, 2026 Clinical update

   Mavorixafor — Phase 3

View all clinical trial activity →

• What is X4 Pharmaceuticals?

  X4 Pharmaceuticals is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker XFOR. Primary therapeutic focus areas include WHIM Syndrome, Neutropenias, Hepatic Insufficiency, Neutropenia, Waldenstrom's Macroglobulinemia. NovaPharmaNews links 11 clinic

• Is X4 Pharmaceuticals publicly traded?

  Yes. X4 Pharmaceuticals is listed with ticker XFOR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does X4 Pharmaceuticals develop or market?

  We link 6 drug profile(s) where X4 Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/x4-pharmaceuticals-inc#company-drugs.

• What are the latest developments for X4 Pharmaceuticals?

  In the last 12 months our linked public records show 11 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does X4 Pharmaceuticals focus on?

  X4 Pharmaceuticals focuses on WHIM Syndrome, Neutropenias, Hepatic Insufficiency based on our analysis of their pipeline programs and drug development activities.